Response to deferoxamine (DFO) therapy of patients who continued to receive transfusions during treatment
| Patient No. . | Diagnosis . | Age, y/Sex . | Initial Ferritin Level (μg/L)* . | TIL before Chelation (mg/kg)† . | TIL during Chelation (mg/kg)† . | UIE after DFO Bolus (μg/48 h) . | UIE after DFO Infusion (μg/48 h) . | Follow-up Time (mo) . | Last Ferritin Value (μg/L)‡ . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | IMF | 61/F | 1705 | 113.1 | 228.1 | 8450 | 6870 | 21 | 570 |
| 3 | MDS, RAEB | 77/M | 2230 | 174.0 | 145.0 | 17 640 | 14 510 | 25 | 1070 |
| 4 | IMF | 61/M | 2100 | 261.0 | 116.0 | 7880 | 11 530 | 21 | 1110 |
| 5 | MDS, RAEB-t | 77/M | 2710 | 152.3 | 186.4 | 4243 | 2556 | 24 | 1320 |
| 6 | CML-CP | 48/F | 1670 | 195.8 | 226.2 | 13 000 | 11 390 | 26 | 930 |
| 7 | NHL-LG | 77/F | 1130 | 95.2 | 181.6 | 4144 | 3737 | 25 | 820 |
| 8 | MDS, RA | 51/F | 685 | 89.8 | 214.9 | 7703 | 6790 | 28 | 615 |
| 9 | MDS, RA | 76/F | 1186 | 93.2 | 118.7 | 10 990 | 8262 | 22 | 620 |
| 10 | IMF | 66/M | 660 | 87.0 | 216.0 | 4360 | 3400 | 20 | 530 |
| 12 | SCA | 24/M | 835 | 96.0 | 121.5 | 5610 | 7360 | 19 | 520 |
| 14 | MDS, RA | 56/F | 2714 | 268.9 | 126.5 | 3800 | 3420 | 16 | 1450 |
| 15 | MDS, RAEB-t | 67/F | 1080 | 87.0 | 101.5 | 7600 | 3610 | 14 | 670 |
| 17 | MDS, RAS | 63/F | 2153 | 232.0 | 130.5 | 11 050 | 13 480 | 19 | 1320 |
| 19 | MDS, RA | 72/F | 2280 | 164.3 | 116.0 | 9920 | 8780 | 12 | 1470 |
| 22 | MDS, RAEB | 73/M | 1390 | 149.1 | 105.6 | 3170 | 3230 | 19 | 730 |
| 1635.2 ± 701.9 | 150.6 ± 64.4 | 155.6 ± 47.6 | 7970.7 ± 4046.4 | 7261.7 ± 3999.9 | 20.7 ± 4.5 | 916.3 ± 347.2 |
| Patient No. . | Diagnosis . | Age, y/Sex . | Initial Ferritin Level (μg/L)* . | TIL before Chelation (mg/kg)† . | TIL during Chelation (mg/kg)† . | UIE after DFO Bolus (μg/48 h) . | UIE after DFO Infusion (μg/48 h) . | Follow-up Time (mo) . | Last Ferritin Value (μg/L)‡ . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | IMF | 61/F | 1705 | 113.1 | 228.1 | 8450 | 6870 | 21 | 570 |
| 3 | MDS, RAEB | 77/M | 2230 | 174.0 | 145.0 | 17 640 | 14 510 | 25 | 1070 |
| 4 | IMF | 61/M | 2100 | 261.0 | 116.0 | 7880 | 11 530 | 21 | 1110 |
| 5 | MDS, RAEB-t | 77/M | 2710 | 152.3 | 186.4 | 4243 | 2556 | 24 | 1320 |
| 6 | CML-CP | 48/F | 1670 | 195.8 | 226.2 | 13 000 | 11 390 | 26 | 930 |
| 7 | NHL-LG | 77/F | 1130 | 95.2 | 181.6 | 4144 | 3737 | 25 | 820 |
| 8 | MDS, RA | 51/F | 685 | 89.8 | 214.9 | 7703 | 6790 | 28 | 615 |
| 9 | MDS, RA | 76/F | 1186 | 93.2 | 118.7 | 10 990 | 8262 | 22 | 620 |
| 10 | IMF | 66/M | 660 | 87.0 | 216.0 | 4360 | 3400 | 20 | 530 |
| 12 | SCA | 24/M | 835 | 96.0 | 121.5 | 5610 | 7360 | 19 | 520 |
| 14 | MDS, RA | 56/F | 2714 | 268.9 | 126.5 | 3800 | 3420 | 16 | 1450 |
| 15 | MDS, RAEB-t | 67/F | 1080 | 87.0 | 101.5 | 7600 | 3610 | 14 | 670 |
| 17 | MDS, RAS | 63/F | 2153 | 232.0 | 130.5 | 11 050 | 13 480 | 19 | 1320 |
| 19 | MDS, RA | 72/F | 2280 | 164.3 | 116.0 | 9920 | 8780 | 12 | 1470 |
| 22 | MDS, RAEB | 73/M | 1390 | 149.1 | 105.6 | 3170 | 3230 | 19 | 730 |
| 1635.2 ± 701.9 | 150.6 ± 64.4 | 155.6 ± 47.6 | 7970.7 ± 4046.4 | 7261.7 ± 3999.9 | 20.7 ± 4.5 | 916.3 ± 347.2 |
TIL indicates total iron load; UIE, urinary iron excretion; IMF, idiopathic myelofibrosis; MDS, myelodysplastic syndrome; RAEB, refractory anemia with excess of blast cells; RAEB-t, refractory anemia with excess of blast cells in transformation to acute myeloid leukemia; CML-CP, chronic myeloid leukemia-chronic phase; NHL-LG, non-Hodgkin lymphoma-low grade; RA, refractory anemia; SCA, sickle cell anemia; and RAS, refractory anemia with ring sideroblasts. Plus-minus values are mean ± SD.
Twelve patients (1-10, 12, 15) were already undergoing DFO iron chelation administered by subcutaneous infusion using a portable pump.
TIL before chelation therapy is expressed as the total amount of iron transfused per kilogram of body weight; TIL during chelation therapy is expressed as the total amount of iron transfused during the follow-up time (months) per kilogram of body weight.
Normal range of serum ferritin concentration, 15-250 μg/L.